UK Alzheimer's drug case ends, judgement reserved

(Reuters) - The judge had been asked to quash the decision of the
National Institute for Health and Clinical Excellence to
restrict access to Alzheimer's drugs on the state National
Health Service.




Manufacturers argued that the way in which NICE reached its
decision to deny drugs costing around $5 a day to NHS patients
newly diagnosed with mild Alzheimer's disease was flawed and
unlawful.


Read more at Reuters.com Government Filings News